All In Biotech

Drug Trial Radar · NCT06712316

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,580 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,580

Planned (sponsor's estimate)

Start

Jan 7, 2025

Primary completion

Jan 2029

Study completion Dec 2031

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • PumitamigDrug

    Intravenous infusion

  • PembrolizumabDrug

    Intravenous infusion

  • CarboplatinDrug

    Intravenous infusion

  • PemetrexedDrug

    Intravenous infusion

  • PaclitaxelDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEsTime frame: From the first dose of the investigational medicinal product (IMP) to the 90-day Follow-Up Visit
  2. Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)Time frame: From the first dose of IMP to the 90-day Follow-Up Visit
  3. Phase 2 - Objective response rate (ORR)Time frame: Up to approximately 2 years
  4. Phase 2 - Best percentage change from baseline in tumor sizeTime frame: Up to approximately 2 years
  5. Phase 3 - Progression free survival (PFS) assessed by BICRTime frame: Up to approximately 5 years

Locations

366 sites in 22 countries. Site status is shown where the registry gives one.

  • Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology

    Birmingham, Alabama · Recruiting

  • Alaska Oncology and Hematology, LLC

    Anchorage, Alaska · Recruiting

  • John Muir Clinical Research Center

    Concord, California · Recruiting

  • University Of California - San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Vail Health

    Vail, Colorado · Recruiting

  • MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)

    Washington D.C., District of Columbia · Recruiting

  • MEDSTAR Washington Hospital Center (MedStar Health Research Institute)

    Washington D.C., District of Columbia · Recruiting

  • Clermont Oncology Center

    Clermont, Florida · Recruiting

  • SSAK Partners, LLC.

    Coral Springs, Florida · Recruiting

  • Baptist Medical Center Jacksonville

    Jacksonville, Florida · Recruiting

  • Mid Florida Cancer Centers

    Orange City, Florida · Recruiting

  • Cleveland Clinic Florida - Martin North Hospital

    Stuart, Florida · Recruiting

  • H. Lee Moffit Cancer center and research institute

    Tampa, Florida · Recruiting

  • Cleveland Clinic Weston Hospital

    Weston, Florida · Recruiting

  • Northwest Georgia Oncology Centers, P.C.

    Marietta, Georgia · Recruiting

  • Fort Wayne Medical Oncology and Hematology, Inc.

    Fort Wayne, Indiana · Recruiting

  • Indiana University Health University Hospital

    Indianapolis, Indiana · Recruiting

  • Physicians Clinic of Iowa

    Cedar Rapids, Iowa · Recruiting

  • Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Baptist Health Hardin

    Elizabethtown, Kentucky · Recruiting

  • Baptist Health Lexington

    Lexington, Kentucky · Recruiting

  • University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center)

    Lexington, Kentucky · Recruiting

  • Frederick Health Hospital- James M Stockman Cancer Institute

    Frederick, Maryland · Recruiting

  • Missouri Cancer Associates

    Columbia, Missouri · Recruiting

  • SSM Health Cancer Care - St. Clare

    Fenton, Missouri · Withdrawn

  • Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC)

    Hastings, Nebraska · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Summit Medical Group PA

    Florham Park, New Jersey · Recruiting

  • The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion

    Paramus, New Jersey · Recruiting

  • Nuvance Health

    Poughkeepsie, New York · Recruiting

  • Suny-Stony Brook University Cancer Center

    Stony Brook, New York · Recruiting

  • White Plains Hospital

    White Plains, New York · Recruiting

  • Fletcher Hospital, Inc. dba AdventHealth Hendersonville

    Hendersonville, North Carolina · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Recruiting

  • The Christ Hospital Cancer Center

    Cincinnati, Ohio · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Dayton Physicians Network

    Dayton, Ohio · Recruiting

  • Kettering Medical Center

    Kettering, Ohio · Recruiting

Showing 40 of 366 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.